Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging
Mauro Salas,1 Jim L Potenziano,2 Jaron Acker3 1Clinical Specialist, Children’s National Health System, Washington, DC, USA; 2Scientific Affairs, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 3Medical Device Marketing, Mallinckrodt Pharmaceuticals, Bedminster, NJ, USACorrespondence: Ma...
Guardado en:
Autores principales: | , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/af2e74d420c64066a3143b344d1e16f1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|